AFIB Company Profile and Key Details

AFIB has shown weak momentum, losing -71.67% over the past week and -78.0% over the past quarter, though year-to-date performance is down -79.69%. Short-term trend indicators are bullishly aligned (SMA20 -60.25%, SMA50 -65.4%, SMA200 -82.79%). The stock’s 14-day RSI is 21.47 (weak momentum), while the ATR of 0.02 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -93.99% below its high and over 16.21% above its low. Average 10-day trading volume of 1.79 thousand shares is below the 3-month average of 5.03 thousand, indicating normal recent market interest.

Acutus Medical, Inc. generated EPS of -$1.25 over the past year. Five-year average earnings growth is -9.95%. The latest quarter delivered EPS of -$0.07. The next quarter is forecast at -$0.50. Next year's EPS is expected at $34.60. Acutus Medical, Inc. earnings surprise history is a mixed track record. The quarter that ended May 09, 2024, missed forecasts by -82.22%.

Acutus Medical, Inc. has 29.91 million shares outstanding. The public float is 24.78 million shares, elevated short interest at 1.91% of float. This equals 553.60 thousand shares. The short ratio is 0.68 days. Institutional investors hold 9.65% of the float. Insiders own 8.28%. Flynn James E holds 1.97 million shares, ORBIMED ADVISORS LLC has 1.68 million shares and Bonita David P has 1.68 million shares.

The stock is currently trading near its 52-week low $0.00 and $0.05. With a market capitalization of about $2.99 thousand, Acutus Medical, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.91). Key stats such as the average daily volume over the past year has been around 2.67 thousand shares, trading with heavier-than-usual volume. Headquartered in Carlsbad, CA, Acutus Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Takeo Mukai, the company employs approximately 85 people and listed since August 06, 2020. Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Our AI price prediction model suggests that Acutus Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by April 15, 2026, within a range of $0.00 to $0.00 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by June 30, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected gain of 4900.0%, with price at $0.01 by April 01, 2027, within a range of $0.00 to $0.03.

Acutus Medical, Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at -0.0, also below market averages.

Acutus Medical, Inc. (NASDAQ:AFIB) shares are down -79.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Acutus Medical, Inc. trading at a premium to the broader market with a P/E of -0.0. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $19.25, suggesting 9624900.0% upside. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term gain (4900.0% over one year), with expected trading ranges indicating moderate volatility.